Tsumura & Co. (Headquarters: Tokyo, President: Junichi Yoshii) today announces a trilateral agreement on the transfer of approval to the production and marketing of ASTAT^® (generic name: Lanoconazole), an external-use anti-fungal drug for ethical use, to Maruho Co., Ltd. (Head office: Osaka, President: Koichi Takagi. Hereinafter "Maruho"). ASTAT^® is jointly developed by Tsumura and Nihon Nohyaku Co., Ltd. (Head office: Tokyo, President: Shukichi Ohuchi. Hereinafter "Nihon Nohyaku") and is made and marketed by Tsumura.

Since September 1994, Tsumura has marketed ASTAT^® by receiving drug substances from Nihon Nohyaku. Available in three forms including ASTAT^® Cream, ASTAT^® Solution and ASTAT^® Ointment, ASTAT^® is extensively used in the treatment of many patients.
At present, Tsumura markets ASTAT^® Cream, ASTAT^® Solution and ASTAT^® Ointment. The above agreement will allow Maruho, from next spring, to market all of the three forms of ASTAT^®, send related information to medical institutions and gather that information.